Mural Oncology plc.
MURA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Mural Oncology plc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel immunotherapies for cancer. The company's lead product candidate is nemvaleukin alfa, an engineered IL-2 cytokine being evaluated in multiple clinical trials for various soli...Show More
Better Health for All
20
Mural Oncology is a clinical-stage oncology company focused on developing immunotherapies for cancer, which are inherently health-positive.
1
While its lead product candidate, nemvaleukin, failed to meet primary endpoints in two Phase II/III trials and was discontinued, the company continues to develop other programs (IL-18, IL-12) aimed at improving patient outcomes.
2
As a clinical-stage company, it does not generate revenue from products with established negative health outcomes. The company's entire R&D budget is dedicated to developing health-improving therapies, with R&D expenses of $165.5 million in 2023 and $167.2 million in 2022.
3
Clinical trials are conducted according to Good Clinical Practice (GCP) regulations, with details on design, patient enrollment, and safety monitoring.
4
Fair Money & Economic Opportunity
0
Mural Oncology plc is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.
1
The provided articles discuss patient assistance programs for investigational treatments and corporate financial filings. There is no evidence that Mural Oncology plc operates as a financial institution or offers lending, deposit, or other financial services to consumers.
2
Therefore, all KPIs related to 'Fair Money & Economic Opportunity' are not applicable to the company's core business.
Fair Pay & Worker Respect
0
No specific, quantitative data points were found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. While some articles mentioned employee sentiment, layoffs, or CEO compensation, they lacked the precise metrics required by the rubric, such as median employee pay, percentage of workforce earning a living wage, or a quantified turnover rate (distinguishing voluntary from involuntary).
1
Fair Trade & Ethical Sourcing
0
No evidence available to assess Mural Oncology plc on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided articles contain no specific, concrete data points or facts related to Mural Oncology plc's performance against the 'Honest & Fair Business' ethical value. Information regarding regulatory fines, transparency benchmarks, whistleblower policies, financial restatements, audit coverage, ESG controversies, complaint resolution, board independence, anti-corruption policies, or third-party verification of ethical claims is absent.
1
Therefore, no KPIs can be scored based on the evidence provided.
Kind to Animals
-40
Mural Oncology plc is listed as engaging in animal testing.
1
While specific details of their animal testing policy are not provided, this indicates that their policy permits such activities, aligning with a tier where testing continues without explicit commitments to reduction or transparency.
No War, No Weapons
0
No evidence available to assess Mural Oncology plc on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantitative data regarding Mural Oncology's environmental performance, such as carbon emissions, renewable energy use, water consumption, waste diversion rates, or climate targets, was found in the provided articles. The articles primarily focus on financial results and clinical trial updates. While an ESG Risk Rating of 26.4 (Medium) from Sustainalytics was noted,
1
this general ESG metric does not map to any specific environmental KPI in the rubric.
Respect for Cultures & Communities
0
No evidence available to assess Mural Oncology plc on Respect for Cultures & Communities.
Safe & Smart Tech
0
No evidence available to assess Mural Oncology plc on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
The provided articles primarily focus on Mural Oncology's financial performance, clinical trial outcomes, and operational restructuring, including significant layoffs and the discontinuation of its lead product candidate.
1
None of the articles contain specific, quantifiable data points or initiatives related to waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education for Mural Oncology plc.
2
An Intertek case study on sustainable laboratory practices was identified, but the results of this study are not explicitly attributed to Mural Oncology plc, and therefore cannot be used as evidence for the company's performance.
3